Interim Report 1st Quarter 2008

May 28, 2008 12:14 ET | Source: Genmab A/S Genmab A/S

In order to read Genmab's Interim Report for the 1st Quarter 2008 please see
the attached file.

Attachments

22_q1_interm_report_2008_uk_final.pdf

22_q1_interm_report_2008_uk_final.pdf...

Recommended Reading

January 21, 2026 06:23 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)...
Read More
January 16, 2026 13:30 ET | Source: Genmab A/S

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 –...
Read More

$Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$